A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer

被引：0
|
作者：
Mackay, H
Major, P
Townsley, C
Mackenzie, M
Vincent, M
Degendorfer, P
Tsao, M
Hedley, D
Wright, J
Oza, A
机构：
[1] Princess Margaret Phase II Consortium, Toronto, ON, Canada
[2] NCI, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3109
引用
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [31] The proteasome inhibitor PS-341 (Velcade®) in the treatment of pancreatic carcinoma.: Critical discussion of a phase II study
    Arit, Alexander
    Foelsch, Ulrich R.
    MEDIZINISCHE KLINIK, 2006, 101 (08) : 668 - 670
  • [32] A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer
    Mackay, H
    Hedley, D
    Major, P
    Townsley, C
    Mackenzie, M
    Vincent, M
    Degendorfer, P
    Tsao, MS
    Nicklee, T
    Birle, D
    Wright, J
    Siu, L
    Moore, M
    Oza, A
    CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5526 - 5533
  • [33] Phase II trial of edatrexate in patients with metastatic colorectal cancer
    Clamon, GH
    Riggs, CE
    Dreicer, R
    Hohl, RJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (04) : 359 - 361
  • [34] Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM).
    Geyer, SM
    Markovic, SM
    Fitch, TR
    Albertini, MR
    Maples, WJ
    Fracasso, PM
    Erlichman, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 716S - 716S
  • [35] The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation
    Bardag-Gorce, F
    Riley, NE
    Nan, L
    Montgomery, RO
    Li, J
    French, BA
    Lue, YH
    French, SW
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2004, 76 (01) : 9 - 16
  • [36] Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Zou, W
    Yue, P
    Lin, N
    He, M
    Zhou, ZM
    Lonial, S
    Khuri, FR
    Wang, BH
    Sun, SY
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 273 - 280
  • [37] Phase II trials of bortezomib (PS-341, Velcade™), a selective proteasome inhibitor, in non-Hodgkin's lymphoma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (02): : 79 - 82
  • [38] Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer
    Meadows, SM
    Mulkerin, D
    Berlin, J
    Bailey, H
    Kolesar, J
    Warren, D
    Thomas, JP
    JOURNAL OF GASTROINTESTINAL CANCER, 2002, 32 (2-3) : 125 - 128
  • [39] Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer
    Sherry Morgan Meadows
    Daniel Mulkerin
    Jordan Berlin
    Howard Bailey
    Jill Kolesar
    Deb Warren
    James P. Thomas
    International Journal of Gastrointestinal Cancer, 2002, 32 : 125 - 128
  • [40] Efficacy of PS-341 in combination with paclitaxel (PAC) and carboplatin (CBDCA) for the treatment of metastatic melanoma (MM): A phase II consortium study
    Maples, W. J.
    Suman, V.
    Croghan, G. A.
    Albertini, M. R.
    Linette, G.
    Flaherty, L. E.
    Eckardt, J.
    Amatruda, T., III
    Erlichman, C. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345